Follicular Synchronization in PCOS Patients Undergoing ICSI
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The use of GnRH antagonist protocol nowadays is the slandered protocol of controlled ovarian
stimulation in patients with poly cystic ovarian syndrome (PCOS) because it decreases the
incidence of OHSS(1, 2). However, this protocol may lead to asynchronous growth of follicles
with an early dominant follicle specially in PCOS patients(3). In most of cases this
phenomenon will affect the IVF outcomes(2, 4) Aromatase inhibitors (AIs) nowadays is
recommended to be used for ovulation induction in patients with PCOS (5, 6).It has fewer side
effects, and a shorter half-life than clomiphene citrate(CC), and no effect ON the
endometrial receptivity. It is used in treating patients with chronic anovulation,
unexplained infertility and poor ovarian reserve(7). It acts through decreasing estrogen
levels and allows follicle stimulating hormone (FSH) release from the hypothalamus (8, 9). It
could be used alone or with combination with human menopausal gonadotropin (HMG) specially in
patients with CC resistant(10-13). It also improves the ovarian response to FSH when they are
used in combination and it decreases the risk of OHSS (14).
This study aims to evaluate the effect of uses of letrozole in combination with HMG during
ovarian stimulation in patients having PCOS undergoing IVF/ICSI on the follicular growth
pattern, synchronized growth of follicles, maturity of oocyte and the quality of embryos.